In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
International Women's Day: An interview with Marelise Epstein
Marelise Epstein is interviewed for International Women's Day and provides a glimpse into her work day and what inspires her.
-
Steve Cutler: ‘People understand what a clinical trial is now’
An interview with CEO Steve Cutler on ICON's recent acquisition of PRA Health Sciences.
-
Inside the Pfizer/BioNTech COVID-19 vaccine trial: ‘We knew the world was watching and waiting for results’
An article featuring commentary from Dr. Nuala Murphy on ICON’s learnings from conducting the Pfizer/BioNTech trial.
-
Mind the gap: Managed access programmes as an alternative to long-term follow up studies
Veronica Gutierrez Martinez and Michael Tokar discuss the challenges of setting up MAPs and the various considerations that must be tackled for a successful programme.
-
Ensuring patient safety and cardiovascular clinical trial integrity during a global pandemic
Jack Martin and Deirdre Albertson provide insights on ensuring patient safety and cardiovascular clinical trial integrity during a global pandemic.
-
Minimising the risk of mistakes in HTA
An article in Pharmexec examining mistakes made in relation to Health Technology Assessments (HTA) and strategies to help reduce risks of future mistakes. ICON’s (ICER’s impact on payer decision making) whitepaper was referenced in the article.
-
How COVID-19 has changed pharmacovigilance
Dr Andrew Garrett contributes to this article in Pharmafocus: How COVID-19 has changed pharmacovigilance. The article explores how drug safety can be ensured while numerous vaccines and treatments come to market in record time to deal with COVID-19.
-
How scientists John Climax and Dr Ronan Lambe created an icon
An article reporting on the growth of ICON as it acquires PRA Health Sciences.
-
-
ICON CEO on PRA deal: Groundwork laid for faster trials (Radio)
A radio intervew with ICON CEO Steve Cutler about the ICON-PRA Health Sciences deal, which is the largest healthcare transaction this year at $12 billion.
